

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number 10/532,009
Filing Date October 22, 2003 (I.A.)
First Named Inventor David S. Lawrence
Art Unit To be assigned
Examiner Name To be assigned
Attorney Docket Number 96700/996

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US- 5,635,608	06-03-1997	Haugland and Gee	
	2	US- 6,258,603 B1	07-10-2001	Carlson et al.	
	3	US- 6,514,722 B2	02-04-2003	Palsson et al.	
	4	US- 2002/0152493 A1	10-17-2002	Keith D. Allen	
	5	US- 2004/0023203 A1	02-05-2004	Miesenbock and Zemelman	
	6	US- 2004/0166553 A1	08-26-2004	Nguyen and McMaster	
	7	US- 5,399,346	03-21-2005	Anderson et al.	
	8	US- 6,242,188 B1	06-05-2001	Dattagupta et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	9	WO 2004/018686 A1	03-04-2004	Cambridge et al.		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Applicant Number	10/532,009		
		Filing Date	October 22, 2003 (I.A.)		
		First Named Inventor	David S. Lawrence		
		Art Unit	To be assigned		
		Examiner Name	To be assigned		
Sheet	2	of	4	Attorney Docket Number	96700/996

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	ADAMS, S.R. and TSIEN, R.Y. (1993) "Controlling Cell Chemistry with Caged Compounds." Annu. Rev. Physiol. Vol. 55. pp 755-84.	
	11	ALBANESE, C. et al. (2002) "Recent advances in inducible expression in transgenic mice." Sem. in Cell & Develop. Biol. Vol. 13. pp 129-41.	
	12	ALBANESE, C. et al. (2000) "Sustained mammary gland-directed, ponasterone A-inducible expression in transgenic mice." FASEB J. Vol. 14, pp 877-884.	
	13	ANDO, H. et al. (2001) "Photo-mediated gene activation using caged RNA/DNA in zebrafish embryos." Nature Genetics. Vol. 28. pp 317-25.	
	14	ARAKAWA, H. et al. (2001) "Mutant loxP vectors for selectable marker recycle and conditional knock-outs." BMC Biotechnol. Vol. 1, No. 7. pp 1472-79.	
	15	BELSHAW, P.J. et al. (1996) "Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization." Chem. Biol. Vol. 3, No. 9. pp 731-38.	
	16	CHEN, J.D. and EVANS, R.M. (1995) "A transcriptional co-repressor that interacts with nuclear hormone receptors." Nature Vol. 377, pp 454-57.	
	17	CRONIN, C.A. et al. (2001) "The lac operator-repressor system is functional in the mouse." Genes Dev. Vol. 15. pp 1506-17.	
	18	CRUZ, F.G. et al. (2000) "Light-Activated Gene Expression." J. Am. Chem. Soc. Vol. 122. pp 8777-78.	
	19	CURLEY, K. and LAWRENCE, D.S. (1999) "Light-activated proteins." Cur. Opin. Chem. Biol. Vol. 3. pp 84-88.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/532,009		
		Filing Date	October 22, 2003 (I.A.)		
		First Named Inventor	David S. Lawrence		
		Art Unit	To be assigned		
		Examiner Name	To be assigned		
Sheet	3	of	4	Attorney Docket Number	96700/996

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	20	DINAN, L. et al. (1999) "An extensive ecdysteroid CoMFA." J. Comput. Aided Mol. Des. Vol. 13. pp 185-207.	
	21	FEIL, R. et al. (1996) "Ligand-activated site-specific recombination in mice." Proc. Natl. Acad. Sci. USA. Vol. 93. pp 10887-90.	
	22	FISHER, G.H. et al. (1999) "Development of a flexible and specific gene delivery system for production of murine tumor models." Oncogene. Vol. 18. pp 5253-60.	
	23	FURUTA, T. et al. (1999) "Brominated 7-hydroxycoumarin-4-ylmethyls: Photolabile protecting groups with biologically useful cross-sections for two photon photolysis." Proc. Natl. Acad. Sci. USA. Vol. 96. pp 1193-1200.	
	24	GINGRICH, J.R. and Roder, J. (1998) "Inducible Gene Expression in the Nervous System of Transgenic Mice." Annu. Rev. Neurosci. Vol. 21. pp 377-405.	
	25	MIKITANI, K. (1996) "A New Nonsteroidal Chemical Class of Ligand for the Ecdysteroid Receptor 3, 5-di-tert-butyl-4-hydroxy-N-isobutyl-benzamide Shows Apparent Insect Molting Hormone Activities at Molecular and Cellular Levels." Biochem. Biophys. Res. Comm. Vol. 227. pp 427-32.	
	26	MONROE, W.T. et al. (1999) "Targeting Expression with Light Using Caged DNA." J. Biol. Chem. Vol. 274. No. 30. pp 20895-20900.	
	27	NAGY, A. (2000) "Cre Recombinase: The Universal Reagent for Genome Tailoring." Genesis. Vol. 26, pp 99-109.	
	28	NO, D. et al. (1996) "Ecdysone-inducible gene expression in mammalian cells and transgenic mice." Proc Natl Acad Sci USA. Vol. 93. pp 3346-51.	
	29	ORSULIC, S. et al. (2002) "Induction of ovarian cancer by defined multiple genetic changes in a mouse model system." Cancer Cell. Vol.1. pp 53-62.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Completion if Known			
		Application Number	10/532,009		
		Filing Date	October 22, 2003 (I.A.)		
		First Named Inventor	David S. Lawrence		
		Art Unit	To be assigned		
		Examiner Name	To be assigned		
Sheet	4	of	4	Attorney Docket Number	96700/996

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	30	PAO, E. et al. (2003) "Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance." Proc. Natl. Acad. Sci. USA. Vol. 100. No. 15. pp 8764-69.	
	31	PETIT, D.L. et al. (1997) "Chemical Two-Photon Uncaging: a Novel Approach to Mapping Glutamate Receptors." Neuron. Vol. 19. pp 465-71.	
	32	RYDING, A.D.S. et al. (2001) "Conditional transgenic technologies." J. Endocrinol. Vol. 171. pp 1-14.	
	33	SAEZ, E. et al. (2000) "Identification of ligands and coligands for the ecdysone-regulated gene switch." Proc. Natl. Acad. Sci. USA. Vol. 97. No. 26. pp 14512-17.	
	34	SHOCKETT, P.E. and Schatz, D.G. (1996) "Diverse strategies for tetracycline-regulated inducible gene expression." Proc. Natl. Acad. Sci. USA. Vol. 93. pp 5173-76.	
	35	WANG, J. et al. (1998) "ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex." Proc. Natl. Acad. Sci. USA. Vol. 95. pp 10860-65.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.